|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DMAC2 |
Gene summary for DMAC2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DMAC2 | Gene ID | 55101 |
| Gene name | distal membrane arm assembly component 2 | |
| Gene Alias | ATP5SL | |
| Cytomap | 19q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | Q9NW81 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55101 | DMAC2 | S014 | Human | Liver | HCC | 2.07e-29 | 7.42e-01 | 0.2254 |
| 55101 | DMAC2 | S015 | Human | Liver | HCC | 1.19e-42 | 1.20e+00 | 0.2375 |
| 55101 | DMAC2 | S016 | Human | Liver | HCC | 2.19e-28 | 6.28e-01 | 0.2243 |
| 55101 | DMAC2 | S027 | Human | Liver | HCC | 9.18e-07 | 4.39e-01 | 0.2446 |
| 55101 | DMAC2 | S028 | Human | Liver | HCC | 1.44e-13 | 4.04e-01 | 0.2503 |
| 55101 | DMAC2 | S029 | Human | Liver | HCC | 5.83e-19 | 5.05e-01 | 0.2581 |
| 55101 | DMAC2 | male-WTA | Human | Thyroid | PTC | 1.25e-05 | 1.06e-01 | 0.1037 |
| 55101 | DMAC2 | PTC01 | Human | Thyroid | PTC | 2.71e-09 | 1.70e-01 | 0.1899 |
| 55101 | DMAC2 | PTC03 | Human | Thyroid | PTC | 1.79e-02 | 1.72e-01 | 0.1784 |
| 55101 | DMAC2 | PTC04 | Human | Thyroid | PTC | 2.43e-03 | 1.40e-01 | 0.1927 |
| 55101 | DMAC2 | PTC05 | Human | Thyroid | PTC | 2.87e-07 | 2.90e-01 | 0.2065 |
| 55101 | DMAC2 | PTC06 | Human | Thyroid | PTC | 1.18e-11 | 2.71e-01 | 0.2057 |
| 55101 | DMAC2 | PTC07 | Human | Thyroid | PTC | 5.11e-12 | 2.68e-01 | 0.2044 |
| 55101 | DMAC2 | ATC09 | Human | Thyroid | ATC | 1.29e-03 | 1.75e-01 | 0.2871 |
| 55101 | DMAC2 | ATC11 | Human | Thyroid | ATC | 5.35e-04 | 3.68e-01 | 0.3386 |
| 55101 | DMAC2 | ATC12 | Human | Thyroid | ATC | 2.56e-04 | 1.42e-01 | 0.34 |
| 55101 | DMAC2 | ATC13 | Human | Thyroid | ATC | 5.07e-25 | 4.49e-01 | 0.34 |
| 55101 | DMAC2 | ATC1 | Human | Thyroid | ATC | 2.78e-04 | 2.04e-01 | 0.2878 |
| 55101 | DMAC2 | ATC2 | Human | Thyroid | ATC | 4.44e-15 | 9.53e-01 | 0.34 |
| 55101 | DMAC2 | ATC3 | Human | Thyroid | ATC | 6.30e-07 | 3.99e-01 | 0.338 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190260017 | Esophagus | HGIN | proton transmembrane transport | 43/2587 | 157/18723 | 5.51e-06 | 1.75e-04 | 43 |
| GO:000915219 | Esophagus | HGIN | purine ribonucleotide biosynthetic process | 43/2587 | 169/18723 | 3.94e-05 | 9.74e-04 | 43 |
| GO:004639019 | Esophagus | HGIN | ribose phosphate biosynthetic process | 46/2587 | 190/18723 | 8.06e-05 | 1.79e-03 | 46 |
| GO:007252216 | Esophagus | HGIN | purine-containing compound biosynthetic process | 47/2587 | 200/18723 | 1.46e-04 | 2.91e-03 | 47 |
| GO:000616416 | Esophagus | HGIN | purine nucleotide biosynthetic process | 45/2587 | 191/18723 | 1.87e-04 | 3.52e-03 | 45 |
| GO:000926019 | Esophagus | HGIN | ribonucleotide biosynthetic process | 43/2587 | 182/18723 | 2.41e-04 | 4.33e-03 | 43 |
| GO:000911720 | Esophagus | HGIN | nucleotide metabolic process | 92/2587 | 489/18723 | 1.11e-03 | 1.36e-02 | 92 |
| GO:00091659 | Esophagus | HGIN | nucleotide biosynthetic process | 53/2587 | 254/18723 | 1.24e-03 | 1.49e-02 | 53 |
| GO:000675320 | Esophagus | HGIN | nucleoside phosphate metabolic process | 93/2587 | 497/18723 | 1.25e-03 | 1.49e-02 | 93 |
| GO:19012939 | Esophagus | HGIN | nucleoside phosphate biosynthetic process | 53/2587 | 256/18723 | 1.49e-03 | 1.73e-02 | 53 |
| GO:000915026 | Esophagus | HGIN | purine ribonucleotide metabolic process | 71/2587 | 368/18723 | 2.00e-03 | 2.11e-02 | 71 |
| GO:000616325 | Esophagus | HGIN | purine nucleotide metabolic process | 75/2587 | 396/18723 | 2.53e-03 | 2.51e-02 | 75 |
| GO:001969320 | Esophagus | HGIN | ribose phosphate metabolic process | 75/2587 | 396/18723 | 2.53e-03 | 2.51e-02 | 75 |
| GO:007252125 | Esophagus | HGIN | purine-containing compound metabolic process | 78/2587 | 416/18723 | 2.78e-03 | 2.73e-02 | 78 |
| GO:000925920 | Esophagus | HGIN | ribonucleotide metabolic process | 71/2587 | 385/18723 | 6.25e-03 | 4.97e-02 | 71 |
| GO:0046034111 | Esophagus | ESCC | ATP metabolic process | 189/8552 | 277/18723 | 1.99e-14 | 1.04e-12 | 189 |
| GO:0006753110 | Esophagus | ESCC | nucleoside phosphate metabolic process | 288/8552 | 497/18723 | 1.80e-08 | 3.50e-07 | 288 |
| GO:0019693111 | Esophagus | ESCC | ribose phosphate metabolic process | 234/8552 | 396/18723 | 4.24e-08 | 7.76e-07 | 234 |
| GO:0009117111 | Esophagus | ESCC | nucleotide metabolic process | 282/8552 | 489/18723 | 4.70e-08 | 8.50e-07 | 282 |
| GO:0009141111 | Esophagus | ESCC | nucleoside triphosphate metabolic process | 78/8552 | 112/18723 | 2.36e-07 | 3.59e-06 | 78 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |